Japan headquartered pharmaceutical company Shionogi & Co. and its European subsidiary, Shionogi B.V. have announced that its innovative antibiotic, FETCROJA (cefiderocol), is now available in Denmark for the treatment of infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options.

Since its European Commission approval in 2020, over 23,000 patients in total have now been treated with cefiderocol throughout Europe. Data from multinational surveillance studies for cefiderocol have demonstrated potent in vitro activity against a broad spectrum of aerobic Gram-negative pathogens including all three WHO critical priority pathogens: carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales, as well as Stenotrophomonas maltophilia. 

Cefiderocol has also demonstrated in vitro activity against certain bacteria that contain very problematic resistant enzymes such as ESBLs, AmpC, serine- and metallo-carbapenemases.

“This launch in Denmark is an important step in rapidly expanding access to cefiderocol across Europe, where we are seeing an increasing trend in the number of antibiotic-resistant infections. Our goal is to ensure availability to clinicians of our new treatment option for all adult patients experiencing aerobic Gram-negative organisms who have limited treatment options.” said Huw Tippett, CEO, Shionogi Europe.